Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash & Current Investments (2023 - 2025)

Historic Cash & Current Investments for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $25.2 million.

  • BioLineRx's Cash & Current Investments fell 1357.76% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year decrease of 1357.76%. This contributed to the annual value of $19.6 million for FY2024, which is 5450.06% down from last year.
  • Per BioLineRx's latest filing, its Cash & Current Investments stood at $25.2 million for Q3 2025, which was down 1357.76% from $28.2 million recorded in Q2 2025.
  • BioLineRx's 5-year Cash & Current Investments high stood at $43.3 million for Q1 2023, and its period low was $19.6 million during Q4 2024.
  • Its 3-year average for Cash & Current Investments is $31.4 million, with a median of $28.8 million in 2023.
  • Over the last 5 years, BioLineRx's Cash & Current Investments had its largest YoY gain of 2030.75% in 2024, and its largest YoY loss of 5450.06% in 2024.
  • BioLineRx's Cash & Current Investments (Quarter) stood at $43.0 million in 2023, then tumbled by 54.5% to $19.6 million in 2024, then rose by 28.88% to $25.2 million in 2025.
  • Its last three reported values are $25.2 million in Q3 2025, $28.2 million for Q2 2025, and $26.4 million during Q1 2025.